摘要
用于肝癌治疗的化疗药物存在水溶性差、全身性毒副作用大、没有病灶靶向性等缺陷.研究制备了三种基于半乳糖骨架的还原响应型纳米前药PGal25D、PGal35D和PGal50D,考察其自组装行为,并以PGal25D为药物载体考察其体外药物释放能力及细胞学水平的肝癌治疗效果.结果表明,三种纳米前药均可形成自组装体,其中PGal25D有良好的粒径、载药能力和稳定性;体外药物释放实验证实PGal25D有良好的还原敏感性;体外细胞毒性结果显示,其对肝癌细胞表现出较好的选择性治疗.
The chemotherapeutic drugs used for liver cancer therapy had several disadvantages,such as poor water solubility,high systemic toxic and lacking of site-specifically delivering.In current study,three kinds of galactose polymeric based reduced-response nano-prodrugs PGal25 D,PGal35 D,and PGal50 D were prepared and investigated for their self-assembly behaviors.PGal25 D was used as a drug carrier to study drug release capability and cytological treatment of liver cancer.The results showed that all the three nano-prodrugs can form self-assembly,in which PGal25 Dhas good particle size,drug-loading ability and stability.In vitro drug release experiments confirmed that PGa25 Dhas good reduction responsibility,while in vitro cytotoxicity results showed that it showed agood therapeutic selectivity for hepatoma cells.
作者
吴婧
李颖
袁嘉怿
陈敬华
WU Jing;LI Ying;YUAN Jia-yi;CHEN Jing-hua(Key Laboratory of Carbohydrate Chemistry and Biotechnology,School of Pharmaceutical Sciences,Jiangnan University,Wuxi 214122,China)
出处
《内蒙古大学学报（自然科学版）》
CAS
北大核心
2018年第5期515-520,共6页
Journal of Inner Mongolia University：Natural Science Edition
基金
国家自然科学基金(21574059)
中央高校基本科研业务费专项资金(JUSRP51709A)资助项目
关键词
含糖高分子
纳米前药
还原响应
肝癌
glycopolymer
nano-prodrug
redox responsibility
liver cancer
